Ombow, The next several days should be interesting for CYDY. Based on the press release, Leronlimab does appear to improve outcomes. Even though the primary endpoint apparently didn't reach statistical significance, 24% is nothing to sneeze at. And there was strong statistical significance in the 'time to recovery' endpoint, reducing hospital stays by 6 days. Also, the 'discharge alive' parameter showed a 28% improvement vrs only 11% for standard of care.
Overall the results sounded promising, especially considering the lack of current Covid therapeutics. Vaccines are well and good, but once a person is severely ill they need new options to improve on the current standard of care.
We'll see what happens to the stock tomorrow. Looking briefly at the I-Hub board, it looks like the remaining shorts are nervous. The longs don't seem especially excited, but their expectations may have been too high. Leronlimab doesn't have to be a cure to get regulatory approvals in the US or other parts of the world.
Btw, the IPIX drug (Brilacidin) is in a similar severe Covid trial, but results won't be out until ~ June, though there could be an interim analysis sooner. Should be extremely interesting to see how Brilacidin performs, not only for the Covid indication, but because it is a broad spectrum anti-viral and anti-bacterial, and uses a 'biomimetic' mechanism with huge potential. Some of the trial sites are in Russia, which could help bypass FDA's anti-therapeutic bias. By summer public interest in Covid treatments will be waning, but Brilacidin has much broader applications. I don't own the stock at the moment, but may get back in with a modest position at some point, subject to position limits of course.
GL with CYDY this week :o)
